ARID1A and Lynch syndrome: In support of this, a complete pathologic response after two months of combined mFOLFOX6 with pembrolizumab therapy was recently reported in a Lynch syndrome patient suffering from an ARID1A mutated and tumor mutational burden (TMB) high dMMR CRC [49].